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Abstract
Charcot–Marie–Tooth disease (CMT) type 2A is a form of peripheral neuropathy, due almost exclusively to dominant
mutations in the nuclear gene encoding the mitochondrial protein mitofusin-2 (MFN2). However, there is no understanding
of the relationship of clinical phenotype to genotype. MFN2 has two functions: it promotes inter-mitochondrial fusion and
mediates endoplasmic reticulum (ER)–mitochondrial tethering at mitochondria-associated ER membranes (MAM). MAM
regulates a number of key cellular functions, including lipid and calcium homeostasis, and mitochondrial behavior. To date,
no studies have been performed to address whether mutations in MFN2 in CMT2A patient cells affect MAM function, which
might provide insight into pathogenesis. Using fibroblasts from three CMT2AMFN2 patients with different mutations in
MFN2, we found that some, but not all, examined aspects of ER–mitochondrial connectivity and of MAM function were
indeed altered, and correlated with disease severity. Notably, however, respiratory chain function in those cells was
unimpaired. Our results suggest that CMT2AMFN2 is a MAM-related disorder but is not a respiratory chain-deficiency
disease. The alterations in MAM function described here could also provide insight into the pathogenesis of other forms of
CMT.
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Introduction
Charcot–Marie–Tooth disease Type 2A (CMT2A; OMIM #609260)
is a neurological disorder that presents as a peripheral neu-
ropathy (1) but involves the central nervous system (2). This
autosomal-dominant disorder is due to heterozygous mutations
in the gene encoding mitofusin-2 (MFN2) (3) but occasionally
MFN2 mutations are recessive (4) or semi-dominant (5). Clini-
cally, patients exhibit progressive sensory loss in the extremi-
ties and pes cavus, among other features (6,7), with the disease
presenting as early- or late-onset forms (8). Studies in relevant
tissues, such as sural nerve, have shown consistent phenotypes
in which chronic axonal atrophy and subsequent regeneration
are often seen (9). Approximately 100 pathogenic mutations in
MFN2 have been described (10), but there is no understanding of
the relationship of clinical phenotype to genotype.
MFN2 and its paralog MFN1 localize to the outer mitochon-
drialmembrane to promote inter-mitochondrial fusion (11). Both
mitofusins protrude into the cytoplasm and establish homo-
typic and heterotypic interactions (12). Importantly, MFN2, but
not MFN1, also localizes to a subdomain of the endoplasmic
reticulum (ER) called mitochondria-associated ER membranes
(MAM) and plays a key role in tethering the two organelles
(13,14). MFN2 contains Ras-binding and GTPase domains, two
transmembrane domains and two heptad repeat (HR) domains
(11) presumably important for inter-mitochondrial fusion (15).
Recently, a re-evaluation of MFN2 topology showed that it has
a single membrane-spanning domain where redox-mediated
disulfide modifications could drive MFN2 oligomerization and
mitochondrial fusion (16,17).
Morphological studies of nervous tissue and fibroblasts from
CMT2A patients with mutations in MFN2 (henceforth denoted
CMT2AMFN2) displayed altered mitochondrial morphology,
including swelling, degeneration and altered distribution of
mitochondria, with an increase in the number of mitochondria
in paranodal extensions of axons, in myelin loops and in
unmyelinated axons (9,18). Interestingly, however, no frag-
mentation of the organelles was observed in those studies,
contrary to what has been observed in cellular models in
which mutated MFN2 was overexpressed (19,20). Mitochondrial
alterations are also apparent in Schwann cells of myelinated
fibers, with the occurrence of needle-like calcium precipitates
and electron-dense lysosome-like structures (21). However,
studies of mitochondria in patient fibroblasts have reported
extremely variable and often contradictory findings, with little
agreement regarding whether or not there are alterations
in MFN2 protein levels (18,22), in respiratory chain capacity
and oxidative phosphorylation (18,22,23), in mitochondrial
membrane potential (23) or in mtDNA content (18,22). In
addition, mitochondrial respiration and MFN2 protein stability
were not affected in HEK-293T cells overexpressing either wild-
type (WT) or pathogenic CMT2A-mutant MFN2 (19).
Studies in transgenic mice have been equally difficult to
interpret. Mice overexpressing a pathogenic mutation in MFN2
(R94Q) associated with CMT2AMFN2 in neurons showed altered
mitochondrial distribution and respiratory chain deficiencies
(24). In mouse dorsal root ganglia overexpressing WT MFN2 or
CMT2AMFN2 proteins, mitochondrial transport, distribution and
morphology along the axons were altered significantly, but ATP
levels and mitochondrial membrane potential were unaffected
(25–27).
Finally,motor neurons derived from induced pluripotent cells
obtained from fibroblasts from a CMT2AMFN2 patient could reca-
pitulate some, but not all, of the disease-related features, includ-
Table 1. Patient and control fibroblasts
Fibroblast Code # Age Sex Mutation Source
Patient P1 32 F R364W M. Shy
Patient P2 60 M M376 V R. Horvath
Patient P3 43 F W740S M. Shy
Control C1 F253-12N R. Horvath
Control C2 F011-11N 45 F R. Horvath
Control C3 AG06858 47 M Coriell
Control C4 AG02261 61 M Coriell
Control C5 AG02222 49 M Coriell
Control C6 CUMC01 30 F CUMC
ing abnormal mitochondrial trafficking and cytoskeletal dis-
tribution, but mitochondrial morphology was unchanged and
many examined phenotypes were relatively mild (28). It is possi-
ble that the heterogeneous findings found in the various CMT2A
models are related to the degree of protein expression and the
ratio between WT and mutant MFN2 species.
As noted above, MFN2 mediates the tethering between
mitochondria and the ER at MAM (13,14). MAM regulates a
number of key cellular functions, among them lipid and calcium
homeostasis, mitochondrial dynamics and bioenergetics (29,30).
More recently it has been shown that MFN2 tethering can
be regulated by post-transcriptional modifications upon non-
degradative ubiquitination of MFN2 by the E3 ligase MARCH5
(31). Notably, loss of MARCH5 reduces ER–mitochondrial
tethering and Ca2+ transfer without affecting mitochondrial or
ER morphology (31). Conversely, in cells lacking MFN2, inter-
oraganellar connectivity and lipid homeostasis are severely
affected (32). It is not known how mutations in MFN2 affect
this communication and whether those potential changes are
related to disease progression. In particular, no examination of
MAM function has been performed, either in cellular models or
in patient cells. To address this gap in our understanding, we
selected fibroblasts from three patients who not only harbored
different mutations in MFN2, but also presented with a variety
of clinical phenotypes, ranging from mild to severe, and studied
them in some detail from both the MAM and mitochondrial
point of view. We felt that this integrated approach could help
explain some of the features associated with the pathogenesis
of CMT2A disease.
Results
Expression of MFN2 mRNA and protein in CMT2AMFN2
fibroblasts
CMT2A is a dominant neuropathy in which patients are
heterozygous for MFN2 mutations, but it is not known whether
the CMT2A phenotype results from MFN2 haploinsufficiency
is a dominant negative effect on the WT allele or is semi-
dominant. To gain more insight into the possible relationship
between the WT and mutant alleles, we analyzed fibroblasts
from three CMT2A patients harboring pathogenic dominant
mutations in MFN2: R364W (patient 1; P1), M376V (P2) and
W740S (P3), and age and sex matched controls (Table 1). The
location of themutation in severely affected patient 1 (at aa-364;
see Materials and Methods) is in the area between the GTPase
domain and HR1; the mutation in moderately affected patient 2
(at aa-376) is located within HR1, in the region required for the
fusion-competent ‘open’ conformation of MFN2 (20); and the
mutation in mildly-affected patient 3 (at aa-740) is in HR2 (33).
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Figure 1. Genetic analysis of CMT2AMFN2 patients. (A) Maps of the human MFN2 gene (exons, gray boxes; size, in kb, above the gene) and the processed mRNA (size,
in nt, below the mRNA). Asterisks denote locations of the mutations in the three CMT2AMFN2 patients. (B) Pherograms of the region in the mRNA encompassing the
indicated mutations (amplified by RT-PCR using the primers denoted by the arrows in A). Note the approximately equal expression of the mRNAs derived from the
WT and mutant alleles (boxed). (C) RFLP analysis of the region of MFN2 mRNA amplified by RT-PCR and cleaved with the indicated restriction enzymes, and whose
cleavage pattern in the gel corresponds to the cleavage map shown above each gel; n = 3, 4 and 3 for R364W, M376V and W740S, respectively. For R364W and M376V,
the % mutation was not significantly different from the expectation of 50%. For W740S, for which no natural restriction site was present, and for which the cDNA was
amplified using a mismatched primer (Supplementary Material, Fig. S2), there was borderline significance (P = 0.049). C, control. M,mutant. Arrows denote various PCR
primers; m, mismatched primer (A).
The heterozygous nature of the mutations was confirmed
by DNA sequencing (Fig. 1A and data not shown). We then
quantified the steady-state levels of MFN2 protein in total
homogenates of controls and the three CMT2AMFN2 patients by
western blot. The total amount of MFN2 protein was unchanged
in patients compared to that in controls (Fig. 2A), nor was that of
its paralog,MFN1 (Supplementary Material, Fig. S1). Importantly,
mitochondrial mass, as measured by the amount of VDAC
protein (Fig. 2A) and themRNA level of themitochondrialmaster
regulator PGC-1α (Fig. 2B), or of mtDNA (Fig. 2C), were unaltered
in the patients. In contrast, average steady-state levels of MFN2
mRNA were ∼2-fold higher in the patients than in controls
(Fig. 2D).
The ∼2-fold increase in MFN2 mRNA was unexpected and
implied that there might be altered expression of MFN2 mRNA
from the WT and mutant alleles. We therefore sequenced
MFN2 cDNA derived from reverse transcription polymerase
chain reaction (RT-PCR) of total mRNA, using MFN2-specific
primers (Fig. 1A and B); in all three patient fibroblasts, we
detected expression from both alleles, in approximately equal
amounts (Fig. 1B). In order to determine whether there was
differential transcription from the WT and mutant alleles, we
performed restriction fragment length polymorphism (RFLP)
analysis of these RT-PCR-amplified cDNAs, using restriction
enzymes that would enable us to distinguish, and quan-
titate, the relative expression from the two alleles (Fig. 1C
and Supplementary Material, Fig. S2). When quantitating the
amount of WT and mutant cDNA derived from the respective
alleles, we were careful to make the proper corrections, both
for fragment size and for formation of heteroduplexes that
were resistant to digestion (see Materials and Methods). For the
R364W (loss of a HpaII site) and M376V (loss of an NlaIII site)
mutations, there were essentially equal steady-state levels of
MFN2 mRNA derived from the WT and mutant alleles (48 ± 8%
and 45 ± 11% mutant, respectively) (Fig. 1C). For the W740S
mutation [gain of a MboI site introduced by the mismatched
PCR primer (Supplementary Material, Fig. S2)], however, there
was a reduction in the steady-state level of the mutant, from
an expected level of 50% to 35 ± 10%, but this value was
at the borderline of significance (n = 3, P = 0.049) (Fig. 1C).
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Figure 2. Analysis of MFN2 expression in CMT2AMFN2 patient fibroblasts. (A) Representative western blots of total protein from fibroblasts from four controls and the
three patients (identified in Table 1), probed for the indicated markers, relative to the expression of α-tubulin and VDAC (predicted molecular masses in parentheses);
20 μg loaded in each lane. Quantitation at right. (B) Expression of total PGC-1α mRNA in patients relative the control average (n = 6; set at 100%). n = 3. (C) Quantitation
of mtDNA relative to control average (n = 5; set at 100%). (D) Expression of total MFN2 mRNA relative to that in the control average (n = 6; set at 100%). Avg., average of
all 3 patients; ∗P < 0.05.
Taken together, we believe that the mutant MFN2 alleles were
expressed at essentially the same steady-state level as the WT
alleles.
Mitochondrial morphology in CMT2AMFN2 fibroblasts
Mouse embryonic fibroblasts (MEFs) lacking Mfn2 have frag-
mented mitochondria (34), whereas expression of the mouse
homologs of various pathogenic human MFN2 mutations
(among them the W740S mutation studied here) in both WT-
MEFs and in double-knockout MEFs lacking Mfn1 and Mfn2
display a variety of morphological phenotypes (19), ranging from
highly tubular to highly aggregated (including W740S, when
overexpressed).We therefore studiedmitochondrialmorphology
in the three patient fibroblasts by confocal microscopy. The
mitochondrial network in the patients’ cells looked similar to
that in the controls (Fig. 3A), as has been observed by others
(18), with no alteration in the length of the organelles (Fig. 3B).
In addition, using electron microscopy (EM), which allows for
the direct observation of organelle morphology, we found that
there was no significant difference in mitochondrial perimeter
or surface area in patients versus controls (Fig. 3C and D).
ER–mitochondrial contacts in CMT2AMFN2 fibroblasts
Aside from its role in inter-mitochondrial fusion, MFN2 partic-
ipates in ER–mitochondrial tethering and communication (13).
In order to examine this aspect of MFN2 function, we assessed
ER–mitochondrial apposition, both by confocal and EM (Fig. 4).
In confocal microscopy, we measured ER–mitochondrial apposi-
tion indirectly, defined as the visual overlap between markers
of ER (in green) and mitochondria (in red) (i.e. yellow). By this
criterion (which admittedly is a relatively low-resolution tech-
nique that allows one to detect inter-organellar distances of only
∼200 nm; 35), the overlap of fluorescent signals was increased in
patient 1 versus controls but was unchanged in patients 2 and 3
(Fig. 4A). It was unclear whether the increased co-localization in
patient 1 was due to a greater number of contacts, an increase in
the length of contacts or some combination of the two.Using EM,
measurement of inter-organellar distance at regions of apposi-
tion [i.e.mitochondria–ER contact (MERC) distance; 36)] showed a
significantly greater distance between the ER and mitochondria
in patients 1 and 3 (Fig. 4B).We also found an increase in both the
length of the inter-organellar contacts (MERC length; 36) and in
the ER–mitochondria contact coefficient (ERMICC), which takes
into account the ER–mitochondrial distance, the length of the
contact and the mitochondrial perimeter (14), in patient 1, but
not in patients 2 or 3 (Supplementary Material, Fig. S3A and B),
consistent with the confocal data.
We also ordered the MERC distances into four size categories
(12–20 nm, 20–40 nm, 40–60 nm and >60 nm) and found that, in
broad view, there were fewer contacts with a cleft width <40 nm
and higher number of contacts >40 nm in all three patients
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Figure 3. Morphology of mitochondria in CMT2AMFN2 patient fibroblasts. (A) Representative confocal microscopy images of the mitochondrial network, as visualized
by anti-TOM20 (shown here in green); 4′ ,6-diamidino-2-phenylindole (DAPI)-stained nuclei are in blue. (B) Mitochondrial length, measured by confocal microscopy.
(C) Mitochondrial perimeter, measured by EM. (D) Mitochondrial surface area, measured by EM.
as compared to controls (Fig. 4B and Supplementary Material,
Fig. S3C), consistent with the greater inter-organellar distances.
Taken together, these data show that these patient cells are
characterized by a lower degree of physical association between
mitochondria and ER as compared to controls.
MAM function in CMT2AMFN2 fibroblasts
The structural analysis of MAM obtained by microscopic
approaches does not take into account the dynamic nature
of ER–mitochondrial communication. As a functional readout
of MAM dynamics, we focused on three hallmarks of MAM
function that would provide such insight, namely phospholipid
transport/synthesis (37,38), cholesteryl ester (CE) synthesis
(32,39) and calcium trafficking (40,41).
Phospholipid synthesis and trafficking. Both mitochondria and
ER play key roles in the synthesis of phosphatidylserine (PtdSer)
and phosphatidylethanolamine (PtdEtn). PtdSer is synthesized
in the MAM; it then translocates to mitochondria, where
it is converted to PtdEtn; PtdEtn then translocates back to
the MAM (37). Therefore, to test directly the effect of MFN2
mutations on phospholipid synthesis mediated by MAM, we
incubated patient and control fibroblasts in medium containing
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Figure 4. ER–mitochondrial connectivity in CMT2AMFN2 fibroblasts. (A) Representative confocal microscopy of ER (anti-PDI; green) and mitochondria (anti-TOM20;
red). Quantification at right. (B) Representative EM pictures of ER and mitochondria in the indicated cells. Quantitation of mitochondria–ER contacts (MERC), a
measurement of inter-organellar distance. The dotted line within the shaded box denotes the control average ± SD (top right), and histograms of the distribution
of ER–mitochondrial distances in the averages of the controls and the patients (bottom right). n = 3; ∗P < 0.05. Other parameters of ER–mitochondrial apposition are
shown in Supplementary Material, Figure S3.
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Figure 5. Phospholipid synthesis in CMT2AMFN2 fibroblasts. Incorporation after
4 h of 3H-Ser into 3H-PtdSer (PS) and 3H-PtdEtn (PE) in the indicated patient
fibroblasts, relative to that of the average in the controls (set at 100%; based on
the data shown in Supplementary Material, Fig. S4). Each data point represents
the value in one experiment (i.e. one or more patients compared to controls, all
analyzed on the same day). Bars indicate average values (n = 3 experiments);
∗P < 0.05 versus control average.
3H-serine and measured the incorporation of the label into
newly-synthesized 3H-PtdSer and 3H-PtdEtn after 2 and 4 h.
In all cells, the degree of incorporation increased over time, as
expected (Supplementary Material, Fig. S4), but there was no
consistent pattern of serine incorporation among the patients.
Specifically, patient 3 had significantly reduced levels of
3H-PtdSer and 3H-PtdEtn compared to controls,which suggests a
reduced crosstalk between ER and mitochondria in this patient,
whereas the other two patients showed little or no reduction
(Fig. 5).
CE synthesis. Cholesterol is converted to CE by acyl-CoA:
cholesterol acyltransferase 1 (ACAT1; gene SOAT1), a MAM-
localized enzyme (39); excess CE are deposited in lipid droplets
(LDs) in the cytosol (32,42). We therefore incubated patient and
control cells with 3H-cholesterol and measured its conversion
into 3H-CE by ACAT1 after 6 h of incubation (Supplementary
Material, Fig. S5). Contrary to what we saw in the phospholipid
transfer assay, we found a significant increase in CE synthesis
in patient 1 and a marginal increase in patient 2, whereas the CE
level in patient 3 was essentially unchanged (Fig. 6).
We also looked for the presence of LDs after staining
cells with HCS LipidTox GreenTM. We detected the most LDs
in fibroblasts from patient 1, and although not statistically
significant, we observed a clear trend toward increased LDs
in the other two patients (Fig. 7A). These data were consistent
with the CE data, in which patient 1 had the greatest CE
synthesis (Fig. 6). In addition, we observed numerous structures
that appeared to be LDs in EM images of patient fibroblasts
compared to control (asterisks in Fig. 7B), plus partially electron-
dense objects that appeared to be autophagosomes containing
what appeared to be LDs (daggers in Fig. 7B), perhaps indicative
Figure 6. CE synthesis in CMT2AMFN2 fibroblasts. Incorporation of 3H-cholesterol
into 3H-CE after 6 h in the indicated patient fibroblasts, relative to that
of the average in the controls (set at 100%; based on the data shown in
Supplementary Material, Fig. S5). Each data point represents the value in one
experiment. Bars indicate average values (n = 3 experiments); ∗P < 0.05 versus
control average.
of lipophagy, similar to what has been reported by others
(21). We note that LDs also accumulate in another peripheral
neuropathy, hereditary sensory neuropathy type 1 (43,44),
which is due to dominant mutations in serine palmitoyltrans-
ferase 1, a protein involved in sphingolipid synthesis (see also
45,46).
Calcium homeostasis. MFN2 modulates intracellular Ca2+ han-
dling, as the ER Ca2+ content in Mfn2-knockout cells is higher
than in WT cells (13). The tethering between the ER and mito-
chondria also impinges on Ca2+ homeostasis by controlling the
transfer of this cation between the two organelles (13,41).
We hypothesized that pathogenic mutations in MFN2 could
affect MAM-mediated Ca2+ trafficking. We first loaded cells
with Fura-2-AM and measured cytosolic Ca2+ in the absence
of any stimuli. In this baseline condition there were no
significant differences in Ca2+ content between patients and
controls (Fig. 8A). Similarly, using D1ER, a calcium-sensitive
(cameleon) probe targeted to the lumen of the ER (47), we saw
no differences in ER Ca2+ content in unstimulated cells from
all three patients (Fig. 8E). In order to monitor mitochondrial
Ca2+ uptake independently of ER content, we first emptied
intracellular Ca2+ stores with 1 μM thapsigargin, an inhibitor
of the sarco/ER calcium ATPase, in Ca2+-free extracellular
buffer. Subsequent Ca2+ addition triggers increases in cytosolic
and mitochondrial Ca2+ that were monitored using cytosolic-
and mitochondrial-targeted aequorin probes, respectively. No
differences were detected in patients versus controls, with
the [Ca2+] within mitochondria mirroring the fluctuations in
cytosolic [Ca2+] (Figs 8C and D).
MFN2 has been implicated in the control of capacitative
calcium entry (CCE; the entry of Ca2+ from the extracellular
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Figure 7. Accumulation of LDs in CMT2AMFN2 fibroblasts. (A) Representative examples of staining of the indicated cells with LipidTox GreenTM. Quantitation of LD
accumulation in control average (dotted line) and patient cells at right. a.u., arbitrary units; ∗P < 0.05. (B) EMs of the indicated cells, showing organelles that appear to
be LDs (asterisks) as well as what appear to be autophagosomes containing LDs (daggers), indicative of lipophagy. Scale bars = 2 μm.
medium upon depletion of intracellular stores) in cells with
dysfunctional mitochondria (48). Whereas the cytosolic Ca2+
levels under resting conditions (‘Rmin’) were essentially un-
changed (Fig. 8A), upon stimulation with thapsigargin CCE was
increased significantly in patients 1 and 2 but not in patient
3 (Fig. 8B). Taken together, the data suggest that there are
only moderate perturbations in calcium homeostasis in this
disorder.
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Figure 8. Calcium homeostasis in CMT2AMFN2 fibroblasts. (A) Measurement of cytosolic Ca2+ in the absence of added Ca2+ or any stimuli, using cells loaded with
Fura-2-AM; changes in [Ca2+] are represented by the 340/380 ratio (Rmin). (B) Measurement of cytosolic Ca2+ upon treatment with 1 μM thapsigargin followed by the
addition of 0.1 mM Ca2+ (i.e. to measure CCE), using cells loaded with Fura-2-AM; [Ca2+] measured as 340/380 ratio (Rmax). (C and D) Measurement of cytosolic Ca2+
and mitochondrial Ca2+ uptake, using cytosolic- and mitochondrial-targeted aequorins, respectively, after depletion of intracellular Ca2+ stores with thapsigargin.
(E) Measurement of ER calcium content. Cells were transfected transiently with D1ER, a cameleon targeted to the ER, and the FRET ratio was measured in the absence
of any stimuli. All results represent mean ± SD of at least three independent experiments. ∗Significant versus the average of all the controls (P < 0.05). In each panel,
the dotted line within the shaded box denotes the control average ± SD.
Mitochondrial respiration in CMT2AMFN2 fibroblasts
MFN2 has been shown to play a key role in activating mitochon-
drial oxidativemetabolism (49–51),which is also regulated by the
connectivity between ER and mitochondria (30). Oscillations in
the trafficking of calcium between ER and mitochondria via the
MAM (29,40,41,52) are signals to induce aerobic metabolism (53),
in part because Ca+2 within mitochondria tightly regulates the
TCA cycle by activating matrix dehydrogenases in most (54), but
not all (55), cells.
We therefore asked if mutations in CMT2AMFN2 fibroblasts
affected bioenergetics. We measured the oxygen consumption
rate (OCR) in patient and control cells using Seahorse technology
(see representative individual experiments in Fig. 9A–C). There
was a significant increase in baseline respiration and after the
addition of specific respiratory complex inhibitors in patient
3, and in baseline OCR in patient 2, whereas the OCRs in
patient 1 were similar to control values (Fig. 9D). Importantly,
the changes in respiration were not due to an alteration in
mitochondrial biogenesis (Fig. 2B), the synthesis of respiratory
chain components (Supplementary Material, Fig. S6), or in
mtDNA content (Fig. 2C). We also calculated the respiratory
control index (RCI), a measure of the coupling of respiration
to phosphorylation. To do that, we first measured baseline OCR
in permeabilized cells via both complex I (i.e. in the presence
of malate + pyruvate) and complex II (i.e. in the presence
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Figure 9. Respiratory chain activity in CMT2AMFN2 fibroblasts. (A–C) Representative Seahorse plots of OCR in the indicated patient and control whole cells using the
Seahorse XF24 analyzer. Oligo, oligomycin; FCCP, carbonylcyanide p-triflouromethoxyphenylhydrazone; A + R, antimycin + rotenone. (D) Quantitation of OCR in whole
patient cells relative to that in the control average (set at 100%). (E) RCI (state 3/state 4) via either complex I or complex II in permeabilized patient fibroblasts relative
to the average of that in five controls. In all experiments n ≥ 3; ∗P < 0.05.
of succinate + rotenone) (both denoted state 2 respiration),
followed by the sequential addition of ADP (state 3 respiration),
oligomycin (state 4 respiration) and FCCP (uncoupled respi-
ration) and calculated the ratio of state 3/state 4 respiration
(i.e. RCI). There was no significant difference in either complex
I- or complex II-mediated RCI between patients and controls
(Fig. 9E).
We also measured mitochondrial membrane potential with
TMRM. We found no difference in the uptake and retention
of this membrane potential-responsive dye in patient versus
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control cells, both in basal conditions and in the presence of
oligomycin+FCCP or antimycin+FCCP (Supplementary Material,
Fig. S7).
Overall, bioenergetic function in these CMT2AMFN2 cells was
not impaired, in agreement with results obtained in Mfn2-
knockout cells (56), and in fact was slightly increased in two
of the three patients, especially under basal conditions.
Discussion
The mechanism(s) underlying the pathogenesis of CMT2A due
to mutations in MFN2 has been elusive. One question has been
the role of mitochondria in the pathogenic process. In particular,
besides alterations in mitochondrial morphology and distribu-
tion, some groups have found that mutations in MFN2 cause
a decrease (23,51,57), an increase (58,59) or no change at all
(18,25), in bioenergetic function. Second, MFN2, either alone or
in partnership with its paralog MFN1, plays at least two dif-
ferent roles in the cell, namely inter-mitochondrial fusion and
ER–mitochondrial tethering at the MAM (13,14), rendering the
deduction of the underlying mechanism(s) particularly difficult.
Yet another confounding issue has been the use of various cellu-
lar and animal models to study the disease, often coupled with
the use of knockout, gene silencing and gene overexpression
paradigms. This is especially problematic when dealing with a
dominantly inherited disorder in which both WT and mutant
alleles are expressed, and whose equilibrium may be important
in determining pathogenesis (5). Finally, little attention has been
paid to the role of MAM-mediated ER–mitochondria interactions
in CMT2AMFN2 disease pathogenesis.
We addressed these issues by focusing on mitochondria
and MAM behavior in fibroblasts derived from CMT2AMFN2
patients. Although fibroblasts may not mimic phenotypes found
in peripheral nerve, we have found that alterations in MAM in
the central nervous system are also seen in MAM present in
non-neuronal tissue, and in fibroblasts in particular (30,32).
Genetically, the analysis of mRNA transcription from the WT
and mutant alleles indicated that there was no diminution of
steady-state levels of the mutant transcripts. Nevertheless, total
MFN2 transcriptionwas doubled (in patients 2 and 3), but protein
levels remained unchanged. This finding implies that there may
be feedback between the amount of protein and the amount
of mRNA produced, especially from the mutant allele, and that
even though there may be a higher dynamic turnover of mutant
transcripts compared to WT, at steady state equal amounts of
WT andmutant protein are produced. This speculationwould be
consistent with a dominant-negative effect of the mutant allele,
as MFN2 functions as a dimer (both with itself and with MFN1).
In addition, our observation that the mitochondrial network in
patient cells appeared normal implies that the endogenous level
of MFN1 homodimers (together with theWTMFN2 homodimers
andWT-MFN2/MFN1 heterodimers) is sufficient to maintain the
mitochondrial network (19).
Our phenotypic data showed that there was great variability
among the three patients, mainly in measurements of ER–
mitochondrial connectivity and MAM functionality (Table 2).
With respect to physical connectivity, ER–mitochondrial co-
localization as measured by confocal microscopy was increased
over controls in patient 1, but not in patients 2 and 3. However,
by EM, two patients (1 and 3) had less, not more, connectivity,
and in all three patients the size distribution of those contacts
was skewed toward greater inter-organellar distance. These
ostensibly conflicting results can be reconciled if confocal
microscopy—a relatively low-resolution technique (35)—of ER–
mitochondrial contacts reflects inter-organellar contact length
more than it does inter-organellar distance, and, in fact, we
had observed this very phenomenon previously (30,32). This
is particularly evident in patient 1, where we found the highest
degree of co-localization by confocalmicroscopy and the highest
ERMICC (which takes into account the length of the contact sites
and the inter-organellar distance) by EM.
While images of ER–mitochondrial connectivity are informa-
tive, they provide only a static snapshot of the two organelles
and do not provide information regarding the highly dynamic
nature of the connections between mitochondria and ER that
can be modulated by local changes in metabolism (60,61) and by
the ‘on–off’ kinetics of the contacts between the two organelles
(30,32). This issue is particularly relevant in CMT2AMFN2,
where WT and mutant MFN2 proteins coexist, but in a currently
unclear relationship. In this regard, the greater inter-organellar
distance described above was also reflected in the dynamic
phospholipid synthesis experiments, most notably in the
reduction in PtdEtn synthesis in patients 2 and 3. Interestingly,
patient 1, with no reduction in PtdEtn synthesis, was the only
one with consistent changes in ER–mitochondrial connectivity,
suggesting that longer segments of contact might be able to
compensate for the greater width separating the two organelles
in this patient.
In contrast to the phospholipid data, there was an increase
in MAM-mediated CE synthesis and LD formation, especially in
patient 1. Thus, even in cells in which phospholipid transfer
was unchanged, ACAT1 activity was increased (i.e. in patients
1 and 2), whereas in cells in which phospholipid transfer was
decreased, ACAT1 activity was unchanged (i.e. in patient 3). We
think that this curious result may actually provide insight into
the mechanism by which MAM regulates its various functions
(discussed further below).
A greater inter-organellar distance implies that functional
biochemical crosstalk between ER andmitochondria ought to be
reduced, including reduced ER–mitochondria Ca2+ exchange
(41). Using a series of Ca2+ reporters targeted to different
subcellular compartments, Ca2+ homeostasis did not appear
to be altered, with the one exception of a significant increase
in CCE [also known as store-operated calcium entry (SOCE)]
(62) in patients 1 and 2. CCE occurs through so-called calcium
release-activated channels (CRACs), which are mediated by the
Ca2+ sensor STIM1, located at the plasma membrane, and the
CRAC subunit ORAI1, located at the ER (63).
With respect to bioenergetics, here too there was variation
among the three patients, similar to the variable results found
by others (18,22,23,58): patients 2 and 3 showed increased basal
respiration (OCR) versus controls, whereas patient 1 showed no
changes. However, the RCI, which is a measure of the coupling
between substrate oxidation and ATP production, showed no dif-
ference versus control in all three patients. Thus, in broad view,
mitochondrial bioenergetics was undiminished in our patients.
We also note that there was an inverse relationship between
OCR and phospholipid transfer/synthesis in patients 2 and 3,
implying that ER–mitochondrial contact plays a role in regulating
bioenergetic output, as has been seen by others (30).
The mitochondrial abnormalities found by us, and by others
(9,51,57), cannot be explained simply as a result of alterations
similar to those seen in authentic mitochondrial disorders due
to respiratory chain deficiency (64). Thus, in broad view, our data
indicate that even though some aspects of bioenergetics may
be perturbed in the disease, CMT2AMFN2 does not behave like an
‘authentic’ mitochondrial respiratory chain disorder (64,65).
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Table 2. Overall summary of data on CMT2AMFN2 patients
Analysis P1 P2 P3 Figure
Patient information
Disease presentation Severe Moderate Mild
MFN2 mutation R364W M376V W740S 1
Genetics
MFN2 mRNA = + + 2D
MFN1 mRNA = = = S1
% mutant MFN2 mRNA (vs 50%) = = = 1C
MFN2 protein = = = 2A
Morphology
Mito length by CM = = = 3B
Mito perimeter by EM = = = 3C
Mito surface area by EM = = = 3D
Mito–ER co-localization by CM + = = 4A
MERC distance by EM + = + 4B
MERC length by EM + = = S3A
ERMICC by EM + = = S3B
MAM-related functions
PtdSer synthesis = = − 5
PtdEtn synthesis = − − 5
ACAT1 activity (CE synthesis) + ± = 6
LD formation + = ± 7
Resting cytosolic Ca2+ = = + 8A
Extracellular Ca2+ uptake (CCE) + + = 8B
Cytosolic Ca2+ after stimulation = = = 8C
Mitochondrial Ca2+ after stimulation = = = 8D
Resting ER Ca2+ (D1ER) = = = 8E
Mitochondrial bioenergetics
Mitochondrial mass = = = 2B
mtDNA content = = = 2C
Basal respiration (OCR) = + + 9D
RCI = = = 9E
Mitochondrial membrane potential = = = S7
No change (=), increased (+), decreased (−), or higher but borderline significance (±) versus controls; CM, confocal microscopy; EM, electron microscopy.
Anothermajor finding of this work is that CMT2AMFN2 cannot
be pigeonholed into a single pathogenic entity, as there was
phenotypic variability among the three patients. However, we
reasoned that patient 1,with themost severe clinical phenotype,
ought to be able to reveal most clearly what relationship, if any,
exists betweenMAMbehavior and pathogenesis. In fact, the data
on patient 1 were contradictory. On the one hand, patient 1 had
the most severe MAM-related phenotypes, namely, significant
alterations in ER–mitochondrial contacts, CE synthesis, LD for-
mation and extracellular calcium uptake. On the other hand,
patient 1 showed no changes in other MAM-related phenotypes,
including phospholipid transfer/synthesis and respiratory chain
function. How can these two sets of data be reconciled?
We note that phospholipid synthesis and bioenergetics are
fundamentally mitochondrial functions, whereas CE synthesis
and LD formation are fundamentally ER functions. Thus, the
two classes of functions could reflect two different aspects of
MAM behavior, one ‘vertical’ (i.e. communication between the
ER and the mitochondria) and the other ‘horizontal’ (i.e. func-
tioning mainly within the MAM subdomain of the ER itself; 32).
For example, phospholipid synthesis/trafficking is fundamen-
tally ‘vertical’; it requires the intimate communication between
both organelles, as the PtdSer that is made in the MAM sub-
domain of the ER is transferred to the mitochondrion, where
it is converted to PtdEtn (37). On the other hand, CE synthesis
is fundamentally ‘horizontal’; it requires the activity of ACAT1,
which is located exclusively in the ER at the MAM subdomain,
with the mitochondria playing essentially no metabolic role in
the process (but likely modulating the lipid composition of the
apposing MAM and MOM membranes; 30). Thus, a reduction in
ER–mitochondrial communication in CMT2AMFN2 might disrupt
‘vertical’ processes more than it does ‘horizontal’ ones. This
hypothesis is the subject of ongoing investigation.
The various phenotypes observed among the three patients
have led us to develop a working model of pathogenesis consis-
tent with the phenotypes seen in the CMT2AMFN2 cells analyzed
here (Fig. 10). We note that ER–mitochondrial communication
in Patient 1, with the severest phenotype, appears to differ
from that in normal cells in two ways: greater inter-organellar
length and greater inter-organellar distance, with the effects on
MAM function of increased contact distance being partially
compensated for by the increased contact length. This could
explain why lipid metabolism and respiration—both ‘vertical’
functions—were essentially normal in this patient, whereas
cholesterol metabolism and LD formation—both ‘horizontal’
functions—were increased. On the other hand, in Patients 2
and 3, with milder clinical phenotypes, contact distance was
increased slightly whereas contact length was unchanged,
which could help explain the reduced phospholipidmetabolism,
the moderate changes in cholesterol metabolism and the
increased respiration.Whether these morphological differences
are related to the location of the mutation within the MFN2
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Figure 10. Working model of pathogenesis in CMT2AMFN2. The severity of the disease may be related to the degree of ER–mitochondrial communication. See text for
details. Key at upper left (nomenclature as in Table 2).
protein is currently unclear. Obviously, much more work needs
to be done, especially in neuronal cultures, to determine the
validity, and the limitations, of the model.
We believe that the altered MAM phenotypes that we
observed in our fibroblasts can be extrapolated to other CMT-
relevant cells, such as sensory neurons and Schwann cells.
Because MAM regulates the synthesis of the main lipid com-
ponents of myelin (30), impairment of the MAM ‘lipid factory’
could well explain why mutations in MFN2, a ubiquitously
expressed protein, could be responsible for the loss of myelin
found in CMT2A (9). In addition reduced levels of PtdEtn could
also affect synaptic vesicle formation and membrane fluidity in
peripheral neurons (66,67). Finally, in a peripheral neuropathy
such as CMT2AMFN2, a possible pathogenetic mechanism is
altered mitochondrial positioning and movement that likely
affect the synaptic function and maintenance (9,25,27,28). The
results reported here are not incompatible with such a view, as
MAM (68) in general, and MFN2 in particular (69), are intimately
associated with mitochondrial dynamics, including movement
along microtubules.
Taken together, our findings could have implications for the
treatment of this disorder and might even provide a conceptual
basis underlying the pathogenesis of both axonal and demyeli-
nating forms of the disease.
Materials and Methods
Patient cells and reagents
Patient 1 is a severely affected 32-year-old female with a R364W
mutation in MFN2. She had normal early developmental mile-
stones and beganwalking independently at 8months of age. Her
parents first noted mobility and balance difficulties at 2 years
7 months of age. She could never ride a bicycle. She has signif-
icant problems with fine motor activity of both hands and has
been unable to cut food by herself since childhood. She requires
a pedestal walker and long leg braces to ambulate. Her voice
has been ‘hoarse’ since age 16, she has documented vocal cord
paralysis and develops shortness of breath after speaking for
several minutes. On neurological examination, she has weak-
ness in biceps and triceps muscles in her upper extremities and
no movements in her intrinsic hand muscles, wrist extensors
or wrist flexors. In her lower extremities she has trace move-
ments of her hamstrings and no movements of her quadri-
ceps, anterior tibialis, gastrocnemius or intrinsic foot muscles.
Small fiber sensory modalities, such as pin prick or light touch,
are essentially normal, with only a mild decrease to pin prick
on her right great toe. Large fiber sensory modalities are pro-
foundly abnormal, as she was unable to detect vibration with a
Rydell tuning fork at her toes, ankles, knees and fingers. Joint
position was absent at her toes and left ankle, and reduced
at both knees. Compound muscle action potential (CMAP) and
sensory nerve action potential (SNAP) amplitudes were unob-
tainable except for a markedly reduced axillar nerve CMAP. Her
CMT Neuropathy score was in the severe range of 28 out of 36
(70).
Patient 2 is a 62-year-old man with a mild clinical presenta-
tion of a M376V mutation in MFN2 that has been described in
detail (71). In brief, he developed progressive bilateral weakness
of his feet and legs, which began at age 11. This was associ-
ated with gradual clawing of his feet, bilateral hand weakness,
bilateral mild numbness of his hands and feet and foot pain. No
bladder or bowel disturbance was reported. His sister, father and
paternal grandmother also had a similar clinical presentation,
suggesting autosomal dominant inheritance. On examination
his cranial nerves were normal. He had a Medical Research
Council (MRC) grade 4/5 weakness and wasting of the intrinsic
muscles of the hand. He also had bilateral pes cavus, wasting of
the calf muscles and MRC grade 4/5 weakness of hip and knee
flexion and extension, and 3/5 weakness in the feet. Achilles
tendon reflexes were absent but the remaining deep tendon
reflexes were normal, with downgoing plantar responses. Mild
sensory loss to pinprickwas present below the elbows and knees.
Vibration sensation was reduced below the ankles, propriocep-
tion was normal throughout and Romberg test was negative.
No cerebellar dysfunction was detected. He had a high step-
ping gait.
Patient 3 is a 43-year-old female with a mild clinical pheno-
type and a W740S mutation in MFN2. Her early milestones were
on time and she participated in all normal activities as a child,
although she was a slow runner. She could ride a bicycle and
ice skate, though not well because of balance. At her recent visit
she noted decreased ability to feel touch from her toes to above
her ankles and that she could no longer wear low-heeled shoes.
She was not wearing ankle support although she felt unstable
walking. She had no problems with finemotor function with her
hands for activities, such as buttoning clothes, fastening jewelry
or cutting food. She noted some difficulty in projecting her voice
loudly. All muscles evaluated in both upper and lower extremi-
ties were graded as full strength (5/5) on neurological examina-
tion. Sensory examination revealed amild reduction to pin prick
and light touch sensation at her toes and decreased but present
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vibratory and position sense at her great toes. Her gait was
judged to be normal except that she could not walk on her heels.
Nerve conduction studies revealed reduced peroneal CMAP,
absent sural and reduced median SNAP amplitudes, but were
otherwise normal. CMT NS was 7 out of 36, in the mild range.
Cell culture and analysis
Information on patient and control fibroblasts are summarized
in Table 1; three of the controls were obtained from the Coriell
Institute for Medical Research (Camden, NJ) and two were from
the Columbia University Medical Center (CUMC). Cells were
grown in Dulbecco’s modified Eagle medium (DMEM) (Gibco
Thermo Fisher Scientific, Rockford, IL; #11995–065) or minimum
essential medium (MEM) (Gibco #11095–080), as indicated. For
western blotting and immunocytochemistry, we used primary
antibodies recognizing MFN1 (Abcam ab104274), MFN2 (Abcam,
Cambridge, United Kingdom; ab50838), TOM20 (Santa Cruz,
Dallas, TX; FL-145), α-tubulin (Sigma-Aldrich; T6199), protein
disulfide isomerase (PDI; Cell Signaling Technology; #3501)
and VDAC1 (Abcam ab15895). For western blot we used anti-
rabbit IgG (Sigma-Aldrich; NA934V) or anti-mouse IgG (Sigma-
Aldrich; NA931V) horseradish peroxidase-linked whole antibody
as secondary antibodies. For immunocytochemestry, we used
Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, Carlsbad, CA;
A-11008) and Alexa Fluor 594 goat anti-mouse IgG (Invitrogen;
A-11005).
Thin layer chromatography (TLC) silica plates were from
EMD Biosciences (Millipore Sigma, Burlington, MA; 5748-
7). PtdSer (#P7769), PtdEtn (#60648), cholesteryl palmitate
(#C6072), cholesteryl oleate (#C9253) and lipid markers for
TLC (#P3817) were from Sigma-Aldrich. Radiolabelled 3H-serine
(NET248005MC) and 3H-cholesterol (NET139001MC) were from
PerkinElmer (Waltham, MA); fatty acid-free bovine serum
albumin (FAF-BSA) was from MP Biomedicals (Santa Ana, CA;
#820472).
Extraction of nucleic acids
Total DNA was extracted from fibroblast cultures by standard
procedures (Puregene; Gentra Systems, Minneapolis, MN)
according to the manufacturer’s instructions. Total RNA was
extracted from fibroblasts using TRIzol Reagent (Invitrogen
15596–018) according to the manufacturer’s instructions. Both
DNA and RNA were quantified with a NanoDrop2000 (Thermo
Fisher Scientific).
MFN2 mutation verification
MFN2 exons (see Fig. 1A) were amplified by PCR using primers
(5′→3′): (RFLP-F-R364W-M376V: CACATGGAGCGTTGTACCAG
and R-Seq R364W-M376M: CAGTAAGAGTCCAAGACTGCAGA;
F-W740S: AGCGTCCTTAGGATGGTGCC and R-W740S: GCTTCATT
CTCTTGGCAGTGGCC) and amplified DNA fragments were
sequenced using the same forward and reverse primers.
Thermal cycles for PCR amplification were 95◦C for 5 min for
initial denaturation; 35 cycles at 95◦C for 30 s each; 55◦C for
annealing and 72◦C for extension.
cDNA synthesis
For RFLP analysis cDNAwas synthesized from total RNA isolated
from cells by a first strand cDNA synthesis kit using oligo-dT as a
primer (Life Technologies Thermo Fisher Scientific) according to
the manufacturer’s protocol. cDNA was amplified using primers
RFLP-F-R364W-M376V: CACATGGAGCGTTGTACCAG; RFLP-R-
R364W-M376V: TCGACCCAGTCCTTCCTCTA; hMFN2-1925F:
CCCTCTCCTTTGGGCTCTAT; and hMFN2-2265R: CCTCAGGTGC-
CCACTATCTG, and sequenced with the same primers.
Quantitative RT-PCR
We obtained cDNA using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA; 4368813,
4374966). Real-time PCR was performed in triplicate, with three
technical replicates per experiment, in a StepOnePlus Real-Time
PCR System (Applied Biosystems; #4376600). The expression
of each gene under study was analyzed using specific MFN2
(Hs00208382) and PGC-1αPPARGC1A; Hs01016719), normalized to
GAPDH expression (Applied Biosystems, 4352339E) as an internal
standard.Mitochondrial DNA content wasmeasured as the ratio
of mitochondrial DNA/nuclear DNA using the following set of
primers and probes: mito F: 5′-CCACGGGAAACAGCAGTGATT-3′;
mito R: 5′- CTATTGACTTGGGTTAATCGTGTGA-3′, Mito-probe:
FAM-TGCCAGCCACCGCG-MGB (custom) and Nuclear-probe:
TaqMan RNAase P control reagent kit (Thermo Fisher Scientific;
#4316831).
RFLP analysis
To determine the level of steady-state transcripts derived from
the WT and mutant MFN2 alleles, we performed RT-PCR on
total RNA with appropriate primers and cleaved the resulting
products with a restriction enzyme specific for either the WT or
mutant alleles. For the R364W mutation, the C→T mutation at
nt-1398 (numbering of GenBank accession #NM 001127660.1)
results in loss of a HpaII site. For the M376V mutation, the
A→G mutation at nt-1434 results in loss of an NlaIII site.
Amplicons for both mutations were obtained using primers
RFLP-F-R364W-M376V and RFLP-R-R364W-M376V. For theW740S
mutation, the G→C mutation at nt-2527 neither creates nor
destroys a restriction site; accordingly, we used a ‘mismatch’
forward PCR primer at this site that introduced an A at nt-2525
instead of a T [5′-GCAAAGCTGCTCAGGAATAAAGCCGGAT-3′;
mismatch in bold (Supplementary Material, Fig. S2)] together
with a reverse primer at the 3′ end of the transcript [5′-
GCTTCATTCTCTTGGCAGTGGCC-3′], resulting in the gain of an
MboI site in the mutant allele. Following polyacrylamide gel
electrophoresis of the cleaved PCR products, we quantitated
the intensity of the fragments by Image J and calculated the
proportion of transcripts derived from each allele. Importantly,
we normalized the intensity of the relevant cleaved fragment
both for length (normalized to the length of its uncleaved
precursor) and for the formation of uncleavable heteroduplexes
(i.e. a ‘square root’ correction of the fraction of total signal
derived from the WT allele, according to the Hardy–Weinberg
law; 72).
Mitochondrial respiration
Respirometry of cultured cells was performed using the XF24e
Extracellular Flux Analyzer (Seahorse Bioscience; Agilent, Santa
Clara, CA). We seeded an equal number of fibroblasts (60 000
cells) in each well. OCR was measured in basal conditions (Sea-
horse media with 2 mm pyruvate and 25 mm glucose) and after
the addition, sequentially, of 1 μm oligomycin, 0.75 μm carbonyl-
cyanide p-triflouromethoxyphenylhydrazone (FCCP) and 1 μm
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rotenone/1 μm antimycin A. All OCR values were normalized to
cell number after the experiment. All results were averages of
at least three technical replicates of more than four biological
replicates.
For permeabilization assays (60 000 cells/well), the culture
medium was replaced by the mitochondrial assay solution
(220 mm mannitol, 70 mm sucrose, 5 mm KH2PO4, 5 mm MgCl2,
2 mm HEPES, 1 mm EGTA and 0.2% FAF-BSA, pH 7.4) containing
10 nm of the XF Plasmamembrane permeabilizer reagent XF PMP
(Seahorse Bioscience #102504–100) and 5 mm malate + 5 mm
pyruvate (for complex I assays) or 5 mm succinate + 2 μm
rotenone (for complex II assays).OCRwasmeasured first with no
added substrates (state 2), and then after the sequential addition
of 3 mm ADP (state 3), 4 μm oligomycin (state 4) and 6 μm FCCP
(uncoupled respiration).
Measurement of mitochondrial membrane potential
For analysis of mitochondrial transmembrane potential, 2000
fibroblasts per well of the indicated genotype were plated
onto 384 well dishes (CellCarrier, PerkinElmer). After 24 h in
culture, cells were loaded with 10 nm of the potentiometric dye
tetramethylrhodamine methylester (TMRM), as described previ-
ously (73,74). Briefly, cells were rinsed in 10 mm HEPES buffered
saline (HBSS buffer, pH 7.4; Invitrogen) and subsequently loaded
with 10 nm TMRM in the presence of 1 μm cyclosporine H
(30 min at 37◦C) and left in the same buffer during image
acquisition. Alternate brightfield and fluorescence (excitation/
emission at 520–550/560–630 nm) images were acquired every
3 min, using the 20× magnification air objective of the
high content screening (HCS) imaging system Operetta® and
Harmony® software (PerkinElmer). Where indicated, cells were
challenged with either 1 μm oligomycin or 2 μm antimycin A;
the ionophore FCCP (2 μm) was added as a control for
mitochondrial depolarization. For image analysis, clusters of
mitochondria were identified as regions of interest and the
average fluorescence intensities after background subtraction
were obtained using the Image J (NIH) software and normalized
for comparative purposes.
Analysis of phospholipid synthesis in cultured cells
Cells were incubated for 2 h with serum-free medium to ensure
removal of exogenous lipids. The medium was then replaced
with MEM containing 2.5 μCi/ml of 3H-serine for the indicated
periods of time. The cells were washed and collected in DPBS,
pelleted at 2500 g for 5 min at 4◦C and resuspended in 0.5 ml
water, removing a small aliquot for protein quantification.
Lipid extraction was done by the Bligh and Dyer method (75).
Briefly, three volumes of chloroform/methanol 2:1 were added
to the samples and vortexed. After centrifugation at 8000 g for
5 min, the organic phase was washed twice with two volumes
of methanol/water 1:1, and the organic phase was blown to
dryness under nitrogen. Dried lipids were resuspended in 60 μl
of chloroform/methanol 2:1 (v/v) and applied to a TLC plate.
Phospholipids were separated using two solvents, composed
of petroleum ether/diethyl ether/acetic acid 84:15:1 (v/v/v)
and chloroform/methanol/acetic acid/water 60:50:1:4 (v/v/v/v).
Development was performed by exposure of the plate to iodine
vapor. The spots corresponding to the relevant phospholipids
(identified using co-migrating standards) were scraped and
counted in a scintillation counter (Packard Tri-Carb 2900TR).
Assay of ACAT activity
To measure ACAT activity in vivo, whole cells were incubated in
serum-free medium for 2 h to remove all exogenous lipids. After
that, 2 μCi/ml of 3H-cholesterol was added to fetal bovine serum
(FBS)-free DMEM containing 2% FAF-BSA, allowed to equilibrate
for at least 30 min at 37◦C, and the radiolabelled medium was
added to the cells for the indicated periods of time. Cells were
then washed and collected in DPBS, removing a small aliquot for
protein quantification. Lipids were extracted as described above
and samples were analyzed by TLC along with an unlabeled CE
standard. A mixture of chloroform/methanol/acetic acid 190:9:1
(v/v/v) was used as solvent. Iodine stains corresponding to CE
bands were scraped and counted.
LD staining
Staining of LDs was performed using HCS LipidTox Deep Green
neutral lipid stain (Invitrogen H34475) according to manufac-
turer’s instructions. LD staining was quantified using ImageJ.
When reported as intensities, the values in the text represent the
product of the intensity and the area covered by the fluorescent
signal above background divided total cell number. For each
cell type, we took between 15 and 20 images for analysis (at
least 5 images per experiment). The images were first taken at
lower magnification (20×) in order to view 50–100 cells per field.
Subsequently, we acquired the images at 63× for quantification.
The numbers reported in the text represent the averages derived
from the quantification of patients versus controls.
Calcium measurements
For CCE measurements, cells were loaded with 2 μm Fura-2-AM
(Thermo Fisher Scientific) in Krebs-Ringer modified buffer (KRB:
125 mm NaCl, 5 mm KCl, 1 mm Na3PO4, 1 mm MgSO4, 5.5 mm
glucose, 20 mm HEPES, pH 7.4) supplemented with 1 mm CaCl2,
250 μm sulfinpyrazone and 0.02% pluronic acid for 30 min at
37◦C. Cytosolic Ca2+ levels were measured in the absence of
stimuli. Cells were then treated with 1 μm thapsigargin in KRB
supplemented with 500 μm EGTA for 5 min at 37◦C, in order
to induce depletion of intracellular Ca2+ stores. Subsequently
CCE was measured upon addition of 1 mm Ca2+. Both basal
cytoplasmic and CCE values are reported as the fluorescence
intensity ratios at 340/380 nm.
Intracellular and mitochondrial Ca2+ were measured using
the calcium reporter aequorin. Cells were seeded in 96 well
plates (10 000 cells per well). After 24 h, cells were infected with
adenoviral particles encoding for cytosolic or mitochondrial-
targeted aequorin-based Ca2+ probes (Italian Ministry of Health
authorization number PD/1C/IMP2/10–001-08/03/10). Thirty-six
h after infection, cells were incubated with 5 μm of the aequorin
cofactor coelenterazine for 1 h in KRB at 37◦C, supplemented
with 1 mm CaCl2. Cells were then washed, treated with 1 μm
thapsigargin in KRB supplemented with 100 μm EGTA. Lumines-
cence from each well was measured for 50 s in an EnVision
microplate reader (PerkinElmer) equipped with a two-injector
unit. After 3 s from the beginning of the experiment, 100 μm
Ca2+ was first injected to elicit an elevation in [Ca2+], and then
a hypotonic, Ca2+-rich, 100 μM digitonin-containing solution
was added to discharge the remaining aequorin pool. The light
signal was collected, calibrated and converted to [Ca2+] values
by an algorithm based on the Ca2+ response curve of aequorin
at physiological conditions of pH, [Mg2+] and ionic strength, as
described (76). Output data were analyzed and calibrated with a
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custom-made macro-enabled Excel workbook. All of the results
are the average of three independent experiments expressed as
mean ± SD.
To measure ER calcium, cells were plated at 3000 cells/well,
with 90 μl of complete medium, in a 384 well plate (Cell Carrier,
PerkinElmer). Twenty-four h after plating, cells were transfected
with a mixture including 0.1 μg of plasmid D1ER, a Forster
resonance energy transfer (FRET)-based Ca2+ probe targeted to
the ER (47), 3 μl of GenJet (SignaGen Laboratories, Rockville,
MD) and 10 μl of FBS-free DMEM. One day later, images were
acquired bymeans of theOperetta High Content Imaging System
(PerkinElmer). Image analysis was performed using Harmony 4.1
Image Analysis Software (PerkinElmer). FRET ratio was calcu-
lated as (FRETcell − FRETbackground) / (CFPcell − CFPbackground), where
the FRET corresponds to the intensity of FRET channel, andCFP is
the intensity of the donor cyan fluorescent protein (47). The two
emission wavelengths were collected with 460–500 nm and 520–
560 nm BandPass filters, respectively. Excitation was achieved
with a Xenon lamp and a 410–430 nm BandPass filter.
Analysis of mitochondrial morphology
Mitochondria were identified by immunocytochemistry using
anti-TOM20, and their lengths were measured using Image J/FIJI
(77). Images were taken using a SP8 confocal microscope (Leica).
Mitochondrial perimeter was measured on EM images, using
MitoLoc together with ImageJ software, as described (78). Experi-
ments were performed on control and patient samples analyzed
side-by-side, run on 3 different days (i.e. n = 3), with 5 technical
replicates per sample.
Analysis of ER–mitochondrial apposition by confocal
microscopy
Cells were fixed in 4% paraformaldehyde and immunostained
with a rabbit antibody to TOM20 to detect mitochondria and
with a mouse antibody to PDI to detect ER. Secondary antibodies
were goat anti-rabbit coupled to Alexa 594 and goat anti-mouse
coupled to Alexa 488. Interactions between mitochondria and
ER were calculated using Image J software (79), determining the
area occupied by one organelle and using its signal as a mask for
the other one, as described (80). The various co-localization data
sets were compared using Mander’s coefficient. Co-localizations
were performed on control and patient samples analyzed side-
by-side, run on 3 different days (i.e. n = 3), with 5 technical
replicates per sample.
Transmission EM
Cells were cultured in 24 well plates. At 70–80% confluency, cells
were washed once with PBS and fixed with pre-heated Fixative
Buffer (0.1 M sodium cacodylate pH 7.4, 2.5% glutaraldehyde)
for 30 min at room temperature. Cells were stored at 4◦C for
90 min before replacing the medium with Storage Buffer (0.1 M
sodium cacodylate pH 7.4). Thin slices of cells obtained after
resin infiltration and polymerization were imaged on a Tecnai-
20 electron microscope (Philips-FEI). Three sets of independent
samples were prepared, and each sample was designated with
a numerical code. Images from 6 different cells (total of 70
images) per sample were collected blinded. Mitochondrial–ER
distancemeasurementswere also carried out blind,using ImageJ
software, setting 150 nm as themaximum distance, as described
previously (14). This type of ‘static’ image analysis was validated
by means of a FRET probe in which the acceptor and donor
fluorophores were located at the surface of either organelle in
live cells; hence, reduced ‘vertical’ distance between the two
corresponds to a decreased FRET ratio (14). The advantage of
using TEM analysis to calculate ERMICC gives us the possibility
of including ER–mitochondrial distance, the length of the con-
tacts and the mitochondrial perimeter in a single value (14,36).
Supplementary Material
Supplementary Material is available at HMG online.
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